Cardiovascular outcomes trials with GLP-1 receptor agonists

This module summarises reported and ongoing GLP-1 receptor agonist CVOTs including lixisenatide (ELIXA), liraglutide (LEADER), semaglutide (SUSTAIN-6) and exenatide (EXSCEL).

Cardiovascular outcomes trials with GLP-1 receptor agonists
Rate this content
  • Cardiovascular outcomes trials with GLP-1 receptor agonists
  • Timeline of new treatment options
  • CVOTs are being conducted for compounds within the newer classes of glucose-lowering agents in patients with T2D
  • CVOTs are being conducted for compounds within the GLP-1 receptor agonist class in patients with T2D
  • GLP-1 receptor agonists have pharmacological differences
Do you want to go to the Presentation Builder section to create a new presentation?
Cancel Go